- Home
- MARPS vs ENVB Comparison
MARPS vs ENVB Comparison
Compare MARPS & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MARPS | ENVB |
|---|---|---|
| Founded | 1956 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 8.1M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | MARPS | ENVB |
|---|---|---|
| Price | $4.48 | $1.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.3K | ★ 134.4K |
| Earning Date | 02-13-2026 | 05-14-2026 |
| Dividend Yield | ★ 6.95% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,914,675.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.39 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.05 | $0.56 |
| 52 Week High | $6.49 | $13.25 |
Technical Indicators
Market Signals| Indicator | MARPS | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 44.60 | 32.44 |
| Support Level | $4.45 | $0.58 |
| Resistance Level | $4.88 | $2.13 |
| Average True Range (ATR) | 0.15 | 0.15 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 45.76 | 17.67 |
Price Performance
Historical ComparisonAbout MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.